The research paper on the broad-spectrum advantages of China Cell's bivalent new crown vaccine SCTV01C was officially published

Article source: Medical Cube Info

The new coronavirus, influenza, and HIV are all RNA viruses, which are prone to errors in the process of virus replication, resulting in virus mutation

At present, the new crown vaccines approved for use at home and abroad are all based on the original strain that first appeared in 2020

The development of a universal vaccine has been a long-term goal of scientists around the world

Due to the huge technical challenges of developing a universal vaccine, the development of a multivalent vaccine has become the most effective and feasible direction to deal with the mutation of the new coronavirus

SCTV01C was developed by Shenzhou Cell Engineering Co.

Antigen design

SCTV01C is a bivalent recombinant protein vaccine based on Alpha variant (B.

The immunogenicity advantage of bivalent new crown vaccine SCTV01C compared with monovalent vaccine in mice

The neutralizing antibody level (antibody titer) in the serum of mice was detected 28 days after inoculation with a single dose of monovalent (Alpha or Beta variant antigen) or bivalent vaccine SCTV01C (Alpha+Beta).

Figure 1 Neutralizing antibody response in mouse serum after inoculation with 1 dose of monovalent vaccine (Alpha or Beta) or SCTV01C

Broad-spectrum advantage of bivalent vaccine SCTV01C compared to monovalent vaccine

After inoculation with 2 doses of monovalent vaccine (Alpha or Beta) or SCTV01C, the neutralizing antibody titers of mouse serum against 14 main variants were detected

Table 1 Neutralizing antibody titers of mouse sera against 14 main mutant strains after inoculation with 2 doses of monovalent vaccine (Alpha or Beta) or SCTV01C

The neutralizing antibody titers of the bivalent vaccine SCTV01C against different variants showed a significant broad-spectrum advantage

Figure 2 Neutralizing antibody titers of mouse serum against 14 main mutant strains after inoculation with 2 doses of monovalent vaccine (Alpha or Beta) or SCTV01C

The bivalent new crown vaccine SCTV01C can induce a strong Th1-dominant cellular immune response

T-cell immune responses, especially Th1-predominant cellular immune responses, play a very important role in the protective effect of 2019-nCoV, as well as reducing severity and mortality after infection, while Th2-biased immune responses are considered to be vaccine-related enhanced respiratory diseases ( VAERD) main reason

Figure 3 T-cell immune responses induced in mice after vaccination with monovalent vaccine (Alpha or Beta) or SCTV01C

According to the announcement of the listed company, on the basis of SCTV01C, China Cell continued to promote the research and development of the new crown vaccine, and developed a new generation of new crown vaccine SCTV01E

The previously published literature shows that the team of Professor Qin Chengfeng of the Academy of Military Medical Sciences of China Cell has also developed the new crown vaccine SCTV01B.

Note: The original text has been deleted

references

[1] https:// https://investors.

[3] Wang R, Sun C, Ma J, Yu C, Kong D, Chen M, Liu X, Zhao D, Gao S, Kou S, Sun L, Ge Z, Zhao J, Li K, Zhang T, Zhang Y , Luo C, Li X, Wang Y, Xie L.

[4] Deng Y, Li J, Sun C, et al.